September 2022 | Targeted Therapies in Oncology

CD20/CD3 Bispecific Antibodies Can Revolutionize B-Cell Lymphoma Therapy

October 03, 2022

Clinical Articles

The bispecific antibodies for B-cell lymphoma that are under development target CD20, and they have a second receptor that targets CD3, which is present on vector T cells, according to Loretta J. Nastoupil, MD.

Progress in Prostate Cancer Care: Highlights From a Decade of Innovation

September 27, 2022

Clinical Articles

Targeted Therapies in Oncology asked some experts in prostate cancer diagnostics and therapeutics for their thoughts on the milestone improvements in treating patients with prostate cancer over the past decade.

Clinical Activity Is Found With Triplet Combination and ADCs in HER2-Mutant MBC

September 24, 2022

Clinical Articles

Results from the SUMMIT basket study revealed encouraging results with a neratinib triplet regimen in patients with HR-positive/ HER2-negative metastatic breast cancer compared with other variations and monotherapies of the 3 drugs.

As CLL Approaches Expand, Sequencing Questions Arise

September 22, 2022

Clinical Articles

Doctors and patients who can stick with a regimen despite relatively minor adverse event will ultimately have more options later in the treatment journey, which could then lead to better long-term outcomes in chronic lymphocytic leukemia.